Neuroprotection and neurorestoration for stroke, TBI and AMD

Nicolas G. Bazan Invited Lectures on Elovanoids in 2019

April 3-7, 2019 - DZNE Scientific Symposium and 10 year Celebration of the DZNE, Bonn, Germany

Title of Lecture: "Specific signals that remodel retinal transcriptome for cell survival upon Amyloid-beta peptide oligomer damage: Elovanoids as molecular guardians"

April 28- May 2, 2019 – ARVO, Association for Research in Vision and Ophthalmology, Vancouver, BC, Canada

Co-Moderator Session: Lipids in Diverse function and pathologies of the eye – SIG (Special Interest Group).

Title of Lecture: “Elovanoids are mediators of the omega-3 lipidome and target transcriptome architecture to sustain photoreceptor function”

and

Session: Lipids and Eye Diseases – Where should we focus? – SIG (Special Interest Group)

Title of Lecture: “Elovanoids act as epigenetic regulators in cell survival/senescence decisions in photoreceptors”

August 22, 2019 – Unity Biotechnology meeting, San Francisco, CA
Title of Lectures - “Brain resiliency in aging and at the onset of damage and of neurodegenerative diseases”

September 20-21, 2019 - VII. International DOG, (Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society -Symposium on Age-Related Macular Degeneration. Understanding Pathogenic Mechanisms of Disease, Baden-Baden, Germany

Distinguished Lecturer – “Elovanoids are novel photoreceptor survival signals relevant to AMD”

September 26, 2019 – Henry Stewart Talks

Title of Talk – Part 1: Photoreceptor protection: Significance of docosanoids and elovanoids

1: Docosahexaenoic acid (DHA) [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4033/.

Title of Talk – Part 2: Photoreceptor protection: Significance of docosanoids and elovanoids

2: Bioactive derivatives of DHA [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4044/.

September 29-October 1, 2019 – The 14th Fatty Acids and Cell Signaling FACS Conference: Fatty Acid Metabolism and Oxidation, Austin, TX

Keynote Lecture – “Elovanoid bioactivity: Significance to Alzheimer’s, traumatic brain injury and Age-related macular degeneration”

October 19-23, 2019 – Society for Neuroscience, Chicago, IL

Oral Presentation: Nanosymposium

Title of Lecture – “The Novel class of homeostatic lipid mediators, elovanoids, provide high-grade neuroprotection in experimental traumatic brain injury”

Abstract Control No.: 3431
Session Title: Traumatic Brain Injury
Location: McCormick Place, Room S404
Session Number: 541
Session Time: 10/22/2019 1:00:00 PM- 10/22/2019 4:15:00 PM

Presentation Number: 541.11
Presentation Time: 10/22/2019 3:30:00 PM- 10/22/2019 3:45:00 PM

*L. S. BELAYEV1, A. OBENAUS2, E. HADDAD2, L. KHOUTOROVA1, V. A. CRUZ FLORES3, P. MUKHERJEE1, N. A. PETASIS4, N. BAZAN1;

October 20-23, 2019 – 16th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, St. Peterburg, FL

Co-Moderator Session 3: Neuronal Inflammation

Title of Lecture – “Elovanoids counteract oligomeric b-amyloid toxicity, regulate transcriptome architecture and function: Significance to Alzheimer’s and Age-related macular degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2020

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Title of Lecture – “Elovanoids are neuroprotective in an experimental model of traumatic brain injury”

Abstract #63

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Ludmila Belayev - Intranasal delivery of elovanoids, novel class of homeostatic lipid mediators, improves neurobehavioral functions and confers neuroprotection on rats with traumatic brain injury

Abstract #64

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Surjyadipta Bhattacharjee - Elovanoids (ELV) protect telomere length shortening and restore of Telomerase activity upon exposure to uncompensated oxidative stress (UOS) or oligomeric amyloid β (Oaβ) recapitulating brain injury.

Abstract #115

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Alexander Ledet - Elovanoids reduce microtubule-associated protein tau (MAPT) missorting.

Abstract #119

March 26, 2020 – Frontiers in Vision Research Lecture Series, Bascon Palmer Eye Institute, University of Miami Health System, Miami, FL
Title of Lecture – “Elovanoids: are molecular guardians of photoreceptor cell integrity: Significance for retinal degenerative diseases”

April 23, 2020 – Schepens/Mass Eye and Ear Institute Distinguished lecture, Harvard University, Boston, MA
Title of Lecture – “Elovanoids modulate the transcriptome of the retina: Significance for retinal degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2019

April 3-7, 2019 - DZNE Scientific Symposium and 10 year Celebration of the DZNE, Bonn, Germany

Title of Lecture: "Specific signals that remodel retinal transcriptome for cell survival upon Amyloid-beta peptide oligomer damage: Elovanoids as molecular guardians"

April 28- May 2, 2019 – ARVO, Association for Research in Vision and Ophthalmology, Vancouver, BC, Canada

Co-Moderator Session: Lipids in Diverse function and pathologies of the eye – SIG (Special Interest Group).

Title of Lecture: “Elovanoids are mediators of the omega-3 lipidome and target transcriptome architecture to sustain photoreceptor function”

and

Session: Lipids and Eye Diseases – Where should we focus? – SIG (Special Interest Group)

Title of Lecture: “Elovanoids act as epigenetic regulators in cell survival/senescence decisions in photoreceptors”

August 22, 2019 – Unity Biotechnology meeting, San Francisco, CA
Title of Lectures - “Brain resiliency in aging and at the onset of damage and of neurodegenerative diseases”

September 20-21, 2019 - VII. International DOG, (Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society -Symposium on Age-Related Macular Degeneration. Understanding Pathogenic Mechanisms of Disease, Baden-Baden, Germany

Distinguished Lecturer – “Elovanoids are novel photoreceptor survival signals relevant to AMD”

September 26, 2019 – Henry Stewart Talks

Title of Talk – Part 1: Photoreceptor protection: Significance of docosanoids and elovanoids

1: Docosahexaenoic acid (DHA) [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4033/.

Title of Talk – Part 2: Photoreceptor protection: Significance of docosanoids and elovanoids

2: Bioactive derivatives of DHA [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4044/.

September 29-October 1, 2019 – The 14th Fatty Acids and Cell Signaling FACS Conference: Fatty Acid Metabolism and Oxidation, Austin, TX

Keynote Lecture – “Elovanoid bioactivity: Significance to Alzheimer’s, traumatic brain injury and Age-related macular degeneration”

October 19-23, 2019 – Society for Neuroscience, Chicago, IL

Oral Presentation: Nanosymposium

Title of Lecture – “The Novel class of homeostatic lipid mediators, elovanoids, provide high-grade neuroprotection in experimental traumatic brain injury”

Abstract Control No.: 3431
Session Title: Traumatic Brain Injury
Location: McCormick Place, Room S404
Session Number: 541
Session Time: 10/22/2019 1:00:00 PM- 10/22/2019 4:15:00 PM

Presentation Number: 541.11
Presentation Time: 10/22/2019 3:30:00 PM- 10/22/2019 3:45:00 PM

*L. S. BELAYEV1, A. OBENAUS2, E. HADDAD2, L. KHOUTOROVA1, V. A. CRUZ FLORES3, P. MUKHERJEE1, N. A. PETASIS4, N. BAZAN1;

October 20-23, 2019 – 16th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, St. Peterburg, FL

Co-Moderator Session 3: Neuronal Inflammation

Title of Lecture – “Elovanoids counteract oligomeric b-amyloid toxicity, regulate transcriptome architecture and function: Significance to Alzheimer’s and Age-related macular degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2020

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Title of Lecture – “Elovanoids are neuroprotective in an experimental model of traumatic brain injury”

Abstract #63

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Ludmila Belayev - Intranasal delivery of elovanoids, novel class of homeostatic lipid mediators, improves neurobehavioral functions and confers neuroprotection on rats with traumatic brain injury

Abstract #64

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Surjyadipta Bhattacharjee - Elovanoids (ELV) protect telomere length shortening and restore of Telomerase activity upon exposure to uncompensated oxidative stress (UOS) or oligomeric amyloid β (Oaβ) recapitulating brain injury.

Abstract #115

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Alexander Ledet - Elovanoids reduce microtubule-associated protein tau (MAPT) missorting.

Abstract #119

March 26, 2020 – Frontiers in Vision Research Lecture Series, Bascon Palmer Eye Institute, University of Miami Health System, Miami, FL
Title of Lecture – “Elovanoids: are molecular guardians of photoreceptor cell integrity: Significance for retinal degenerative diseases”

April 23, 2020 – Schepens/Mass Eye and Ear Institute Distinguished lecture, Harvard University, Boston, MA
Title of Lecture – “Elovanoids modulate the transcriptome of the retina: Significance for retinal degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2019

April 3-7, 2019 - DZNE Scientific Symposium and 10 year Celebration of the DZNE, Bonn, Germany

Title of Lecture: "Specific signals that remodel retinal transcriptome for cell survival upon Amyloid-beta peptide oligomer damage: Elovanoids as molecular guardians"

April 28- May 2, 2019 – ARVO, Association for Research in Vision and Ophthalmology, Vancouver, BC, Canada

Co-Moderator Session: Lipids in Diverse function and pathologies of the eye – SIG (Special Interest Group).

Title of Lecture: “Elovanoids are mediators of the omega-3 lipidome and target transcriptome architecture to sustain photoreceptor function”

and

Session: Lipids and Eye Diseases – Where should we focus? – SIG (Special Interest Group)

Title of Lecture: “Elovanoids act as epigenetic regulators in cell survival/senescence decisions in photoreceptors”

August 22, 2019 – Unity Biotechnology meeting, San Francisco, CA
Title of Lectures - “Brain resiliency in aging and at the onset of damage and of neurodegenerative diseases”

September 20-21, 2019 - VII. International DOG, (Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society -Symposium on Age-Related Macular Degeneration. Understanding Pathogenic Mechanisms of Disease, Baden-Baden, Germany

Distinguished Lecturer – “Elovanoids are novel photoreceptor survival signals relevant to AMD”

September 26, 2019 – Henry Stewart Talks

Title of Talk – Part 1: Photoreceptor protection: Significance of docosanoids and elovanoids

1: Docosahexaenoic acid (DHA) [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4033/.

Title of Talk – Part 2: Photoreceptor protection: Significance of docosanoids and elovanoids

2: Bioactive derivatives of DHA [Video file]. In The Biomedical & Life Sciences Collection. Henry Stewart Talks. Retrieved October 2, 2019, from https//hstalks.com/bs/4044/.

September 29-October 1, 2019 – The 14th Fatty Acids and Cell Signaling FACS Conference: Fatty Acid Metabolism and Oxidation, Austin, TX

Keynote Lecture – “Elovanoid bioactivity: Significance to Alzheimer’s, traumatic brain injury and Age-related macular degeneration”

October 19-23, 2019 – Society for Neuroscience, Chicago, IL

Oral Presentation: Nanosymposium

Title of Lecture – “The Novel class of homeostatic lipid mediators, elovanoids, provide high-grade neuroprotection in experimental traumatic brain injury”

Abstract Control No.: 3431
Session Title: Traumatic Brain Injury
Location: McCormick Place, Room S404
Session Number: 541
Session Time: 10/22/2019 1:00:00 PM- 10/22/2019 4:15:00 PM

Presentation Number: 541.11
Presentation Time: 10/22/2019 3:30:00 PM- 10/22/2019 3:45:00 PM

*L. S. BELAYEV1, A. OBENAUS2, E. HADDAD2, L. KHOUTOROVA1, V. A. CRUZ FLORES3, P. MUKHERJEE1, N. A. PETASIS4, N. BAZAN1;

October 20-23, 2019 – 16th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases, St. Peterburg, FL

Co-Moderator Session 3: Neuronal Inflammation

Title of Lecture – “Elovanoids counteract oligomeric b-amyloid toxicity, regulate transcriptome architecture and function: Significance to Alzheimer’s and Age-related macular degeneration”

Nicolas G. Bazan Invited Lectures on Elovanoids in 2020

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Title of Lecture – “Elovanoids are neuroprotective in an experimental model of traumatic brain injury”

Abstract #63

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Ludmila Belayev - Intranasal delivery of elovanoids, novel class of homeostatic lipid mediators, improves neurobehavioral functions and confers neuroprotection on rats with traumatic brain injury

Abstract #64

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Surjyadipta Bhattacharjee - Elovanoids (ELV) protect telomere length shortening and restore of Telomerase activity upon exposure to uncompensated oxidative stress (UOS) or oligomeric amyloid β (Oaβ) recapitulating brain injury.

Abstract #115

February 27-29, 2020 – 15th Annual Conference on Brain Injury, “Best Practices in Brain Injury Medicine and Neurorehabilitation: Improving Outcomes through Interdisciplinary Collaboration, New Orleans, LA
Alexander Ledet - Elovanoids reduce microtubule-associated protein tau (MAPT) missorting.

Abstract #119

March 26, 2020 – Frontiers in Vision Research Lecture Series, Bascon Palmer Eye Institute, University of Miami Health System, Miami, FL
Title of Lecture – “Elovanoids: are molecular guardians of photoreceptor cell integrity: Significance for retinal degenerative diseases”

April 23, 2020 – Schepens/Mass Eye and Ear Institute Distinguished lecture, Harvard University, Boston, MA
Title of Lecture – “Elovanoids modulate the transcriptome of the retina: Significance for retinal degeneration”

NeuResto Therapeutics

Large Unmet Clinical Needs in Stroke, Traumatic Brain Injury (TBI) and Age-related Macular Degeneration (AMD)

Investigational medical device not cleared for human use

As there are no approved TBI therapies, the current standard is 'rest.' Repeated concussions can lead to cognitive impairment and other neurodegenerative diseases.

With nearly 4 million annual cases of TBI in the USA, our novel approach, intranasal delivery of elovanoids, addresses a large unmet clinical need.

Ischemic Stroke

Traumatic Brain Injury (TBI)

Age-related Macular Degeneration (AMD)

Current therapy for ischemic stroke is thrombolysis (tPA) and mechancal thrombectomy.

However, only 10% of all ischemic stroke patients (795,000 patients in US) currently undergo thrombectomy, which has become the standard of care since 2015. Of these patients, at best 40-50% are helped with this approach. Additionally, many are turned down for not having sufficient ‘salvageable’ brain tissue (penumbra).

No current therapy for TBI (concussion) except 'rest.'

There is no current therapy that can halt or improve vision in dry AMD

Few effective options exists for patients with ischemic stroke and most do not receive it

Use of elovanoids for other neurodegenerative diseases with no current therapies, such as Alzheimer's, Parkinson's and other neurodegenerative diseases

Despite decades of research, there is still no promising therapy for Alzheimer's

(Below, from our research group, left) Neurons in Alzheimer's disease and right) Degenerating dopaminergic-neurons of Parikinson's Disease)

AMD is #1 cause of blindness in Caucasians over the age of 65 in the USA (~11 million).

For dry AMD (85-90% of all AMD), there is no treatment except vitamins, which can only slow it down marginally – at best.

Currently, only neovascular ('wet') AMD can be treated, but not neurodegenerative ('dry') AMD, that affects the majority of AMD patients.